Updated Jul 16, 2026 · Last SEC filing 2026-07-02
ARS Pharmaceuticals, Inc. (SPRY) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 4 Form 8-K material event filings were reported by SPRY in the last 90 days. 2 Form 144 notices of proposed sale were filed for SPRY stock. InsiderAlpha tracks every SPRY SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001671858 |
| Form 4 filings (90d) | 12 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 2 |
| Latest Form 4 filing | 2026-07-02 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Fitzpatrick Alexander A | Chief Legal Officer | S — Open-market sale | 3.4K | $10.00 | $34K | SEC | |
| Karas Eric | Chief Commercial Officer | S — Open-market sale | 25.0K | $10.00 | $250K | SEC | |
| Karas Eric | Chief Commercial Officer | M — Option exercise | 25.0K | $1.50 | $38K | SEC | |
| Scott Kathleen D. | Chief Financial Officer | M — Option exercise | 12.5K | $1.50 | $19K | SEC | |
| Lowenthal Richard E | PRESIDENT AND CEO | S — Open-market sale | 50.0K | $14.49 | $724K | SEC | |
| Scott Kathleen D. | Chief Financial Officer | S — Open-market sale | 12.5K | $15.00 | $188K | SEC | |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | S — Open-market sale | 37.7K | $14.09 | $531K | SEC | |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | S — Open-market sale | 12.3K | $14.03 | $173K | SEC | |
| Karas Eric | Chief Commercial Officer | S — Open-market sale | 15.0K | $16.99 | $255K | SEC | |
| Karas Eric | Chief Commercial Officer | M — Option exercise | 15.0K | $1.50 | $22K | SEC | |
| Flynn James E | 10% Owner | S — Open-market sale | 370.1K | $18.46 | $6.83M | SEC | |
| Flynn James E | 10% Owner | S — Open-market sale | 370.1K | $18.46 | $6.83M | SEC | |
| SAUNDERS BRENT L | Insider | M — Option exercise | 120.0K | $1.01 | $121K | SEC | |
| SAUNDERS BRENT L | Insider | S — Open-market sale | 120.0K | $14.25 | $1.71M | SEC | |
| Lowenthal Richard E | PRESIDENT AND CEO | S — Open-market sale [10b5-1] | 50.0K | $11.67 | $584K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for ARS Pharmaceuticals, Inc. (SPRY). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Karas Eric | 3 | $288K |
| Thompson Peter A. | 1 | — |
| Islam Saqib | 1 | — |
| SAUNDERS BRENT L | 1 | — |
| RA CAPITAL MANAGEMENT, L.P. | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SPRY insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live SPRY dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.